Literature DB >> 9445071

Genetic determinants responsible for acquisition of dengue type 2 virus mouse neurovirulence.

M Bray1, R Men, I Tokimatsu, C J Lai.   

Abstract

Studies conducted some 50 years ago showed that serial intracerebral passage of dengue viruses in mice selected for neurovirulent mutants that also exhibited significant attenuation for humans. We investigated the genetic basis of mouse neurovirulence of dengue virus because it might be directly or indirectly associated with attenuation for humans. Analysis of the sequence in the C-PreM-E-NS1 region of the parental dengue type 2 virus (DEN2) New Guinea C (NGC) strain and its mouse-adapted, neurovirulent mutant revealed that 10 nucleotide changes occurred during serial passage in mice. Seven of these changes resulted in amino acid substitutions, i.e., Leu55-Phe and Arg57-Lys in PreM, Glu71-Asp, Glu126-Lys, Phe402-Ile, and Thr454-Ile in E, and Arg105-Gln in NS1. The sequence of C was fully conserved between the parental and mutant DEN2. We constructed intertypic chimeric dengue viruses that contained the PreM-E genes or only the NS1 gene of neurovirulent DEN2 NGC substituting for the corresponding genes of DEN4. The DEN2 (PreM-E)/DEN4 chimera was neurovirulent for mice, whereas DEN2 (NS1)/DEN4 was not. The mutations present in the neurovirulent DEN2 PreM-E genes were then substituted singly or in combination into the sequence of the nonneurovirulent, parental DEN2. Intracerebral titration of the various mutant chimeras so produced identified two amino acid changes, namely, Glu71-Asp and Glu126-Lys, in DEN2 E as being responsible for mouse neurovirulence. The conservative amino acid change of Gu71-Asp probably had a minor effect, if any. The Glu126-Lys substitution in DEN2 E, representing a change from a negatively charged amino acid to a positively charged amino acid, most likely plays an important role in conferring mouse neurovirulence.

Entities:  

Mesh:

Year:  1998        PMID: 9445071      PMCID: PMC124649     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Recent advances in our knowledge of dengue and sandfly fever.

Authors:  A B SABIN
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions.

Authors:  F Guirakhoo; F X Heinz; C W Mandl; H Holzmann; C Kunz
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

3.  Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus.

Authors:  K Stiasny; S L Allison; A Marchler-Bauer; C Kunz; F X Heinz
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus.

Authors:  C J Lai; B T Zhao; H Hori; M Bray
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein.

Authors:  E Lee; R C Weir; L Dalgarno
Journal:  Virology       Date:  1997-06-09       Impact factor: 3.616

6.  A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.

Authors:  R Edelman; C O Tacket; S S Wasserman; D W Vaughn; K H Eckels; D R Dubois; P L Summers; C H Hoke
Journal:  J Infect Dis       Date:  1994-12       Impact factor: 5.226

7.  Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis.

Authors:  B Falgout; M Bray; J J Schlesinger; C J Lai
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Dengue virus premembrane and membrane proteins elicit a protective immune response.

Authors:  M Bray; C J Lai
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 9.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

Authors:  A B Sabin; R W Schlesinger
Journal:  Science       Date:  1945-06-22       Impact factor: 47.728

View more
  30 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease.

Authors:  Vanessa V Sarathy; Mellodee White; Li Li; Summer R Gorder; Richard B Pyles; Gerald A Campbell; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

4.  A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis.

Authors:  Dixon Grant; Grace K Tan; Min Qing; Jowin K W Ng; Andy Yip; Gang Zou; Xuping Xie; Zhiming Yuan; Mark J Schreiber; Wouter Schul; Pei-Yong Shi; Sylvie Alonso
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

5.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Authors:  F Guirakhoo; R Weltzin; T J Chambers; Z X Zhang; K Soike; M Ratterree; J Arroyo; K Georgakopoulos; J Catalan; T P Monath
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 7.  Mouse models of dengue virus infection for vaccine testing.

Authors:  Vanessa V Sarathy; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

8.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Infection dynamics of sylvatic dengue virus in a natural primate host, the African Green Monkey.

Authors:  Kathryn A Hanley; Mathilde Guerbois; Tiffany F Kautz; Meredith Brown; Stephen S Whitehead; Scott C Weaver; Nikos Vasilakis; Preston A Marx
Journal:  Am J Trop Med Hyg       Date:  2014-08-04       Impact factor: 2.345

10.  Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice.

Authors:  Smita Jaiswal; Todd Pearson; Heather Friberg; Leonard D Shultz; Dale L Greiner; Alan L Rothman; Anuja Mathew
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.